Crizotinib, an adenosine-triphosphate (ATP)-competitive smallmolecule inhibitor, was the first oral ALK inhibitor approved by the Food and Drug Administration (FDA) inAugust 2011 for the treatment of NSCLC to inhibit the receptor tyrosine kinasesALK, ROS1, and mesenchymal-epithelial transition (MET) [5, 6, 7, 8, 9]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.